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Journal of Stroke and CBackground: Atrial fibrillation (AF) is a cardiac arrhythmia that frequently induces
ischemic strokes. Nowadays, non-vitamin K antagonist oral anticoagulants
(NOACs) have come into widespread use for cardiogenic embolism prevention in
place of warfarin. Recently, cerebral microbleeds (CMBs) have been noticed for their
potential implication in cerebral small vessel disease. We hypothesized that NOACs
do not have an unfavorable influence over cerebral small vessels and investigated
whether NOACs increase CMBs in AF patients in a prospective manner. Methods:
We performed baseline magnetic resonance imaging (MRI) examinations on the
69 enrolled AF patients and re-examined second round of MRI 1 year later. The
enrolled patients continued the same anticoagulation therapy during the meantime.
Results: CMBs did not develop in the 23 patients with NOACs for 1 year. Nine
patients with antiplatelets also did not develop CMBs. On the other hand, 3 of 21
patients continued on warfarin and 3 of 9 with warfarin and antiplatelets had
CMBs. When divided into 2 groups according to whether the CMBs developed,
significant differences in the incidence of using NOACs were observed between
the 2 groups (P 5 .02). A multivariate regression analysis showed that warfarin
was independently related to the new development of CMBs (hazard ratio, 10.75;
95% confidence interval, 1.22-94.99; P 5 .03). Conclusions: This is the first report to
clarify that NOACs do not increase CMBs in AF patients longitudinally in 1 year.
Further consideration will be continued with a much longer follow-up in large
samples. Key Words: NOAC—warfarin—cerebral microbleeds—atrial fibrillation.
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Atrial fibrillation (AF) is a cardiac arrhythmia that
frequently induces ischemic strokes because of hemosta-
sis or excessive blood clotting being prone to promote
left atrial thrombosis. Heretofore, warfarin as an anticoag-
ulant has been used to prevent cardiogenic embolism in
AF patients. Nowadays, non-vitamin K antagonist oral
anticoagulants (NOACs), formerly stood for ‘‘novel orallar, Respiratory and Neurology Division,
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T. SAITO ET AL.1374myocardial infarction, peripheral artery disease, or aortic
plaque], sex category [ie, female sex] and 2 points for a
prior stroke or transient ischemic attack or thromboembo-
lism and an age$75 years) score4-6 has come into general
use for the risk assessment in nonvalvular AF patients
because CHA2DS2-VASc score predicts future cardio-
genic embolisms more accurately than the formerly
used CHADS2 score.
7 The CHA2DS2-VASc score makes
us aware that some of its components also play a key
role in focal cerebral microangiopathy.
Cerebral microbleeds (CMBs) are seen as small, from
2 to 5 mm in diameter, round foci with hypointensity
on the gradient echo T2*-weighted magnetic resonance
imaging (MRI).8,9 CMBs are believed to represent
perivascular accumulation of hemosiderin-containing
macrophages on histopathologic examinations,10-12 and
therefore, they are considered to suggest the existence of
vulnerability of the cerebral small vessels. We indicated
the possibility that AF itself aggravates cerebral small
vessels and significantly encompasses an increase in the
CMBs as a consequence,13 whereas only a few reports
have addressed focal cerebral microangiopathy in AF
patients.
The incidence of intracranial bleeding during
NOAC treatment is uniformly lower than that during
warfarin treatment.1-3 Furthermore, there is a report that
a hematoma that arises because of acute intracranial
bleeding during dabigatran treatment tends to remain
small and hard to expand.14 We hypothesized that
NOACs do not have an unfavorable influence over cere-
bral small vessels. Under this hypothesis, we defined
that the goal in the present study was to prove that
NOACs do not increase CMBs in AF patients in a pro-
spective manner while considering the association of
the CHA2DS2-VASc.
Methods
The entire study protocol was approved by the Ethical
Review Board of the Asahikawa Medical University, and
all patients gave their written informed consent for the
study.
Patient Enrollment and the Longitudinal Study
A brain MRI assessment was performed on the
outpatients older than 45 years with AF who visited the
Cardiovascular, Respiratory, and Neurology Divisions of
Asahikawa Medical University Hospital, and they were
consecutively enrolled in the study. Valvular AF patients
were excluded. A baseline MRI examination was per-
formed on the patients enrolled, and 1 year later, a second
round of MRI examinations were performed and
analyzed changes in the number of CMBs with informed
consent. The enrolled patients continued the same anti-
coagulation therapy for the prevention of cardiogenic
embolism in the study period.Definition of the Variables
Hypertension was defined as a systolic blood pressure
of 140 mm Hg or more and/or diastolic blood pressure
of 90 mm Hg or more in subjects who were not taking
antihypertensive medications or continuously receiving
antihypertensive treatment on an outpatient basis.
Diabetes mellitus was defined as a Japan Diabetes Society
hemoglobin A1c value of 6.1 or more (corresponds
approximately to the National Glycohemoglobin Stan-
dardization Program hemoglobin A1c value of $6.5) or
any continuous antidiabetic treatment on an outpatient
basis. Chronic kidney disease was defined as an esti-
mated glomerular filtration rate level of less than
60 ml/min/1.73 m2 and/or overt albuminuria continuing
longer than 3 months. Congestive heart failure was
defined as that previously diagnosed by a cardiovascular
specialist.MRI Assessment
The MRI assessments were performed by trained
observers who were blinded to the clinical information
(J.S. and T.K.). We adopted the recommended criteria
for the identification of CMBs proposed by Greenberg
et al8 to precisely assess the number of CMBs: (1) a black
lesion on the T2*-weighted MRI, (2) round or ovoid
lesions (rather than linear), (3) a blooming effect of the
T2*-weighted MRI, (4) signals devoid of hyperintensity
on the T1-weighted or T2-weighted sequences, (5) at least
half of the lesion surrounded by brain parenchyma, (6)
distinct from other potential mimicking conditions such
as iron or calcium deposits, bone, or vessel flow voids,
and (7) a clinical history excluding any traumatic diffuse
axonal injury. CMBs were categorized into 2 groups: lobar
(cortex, subcortex, and white matter) CMBs and deep or
infratentorial CMBs. A cerebral infarction was defined
as a focal lesion with a hypointense lesion with a hyper-
intense rim in the fluid-attenuated inversion recovery
sequence images, with a corresponding hyperintensity
on the T2-weighted images and corresponding hypoin-
tensity on the T1-weighted images. Cerebral infarctions
with no plausible clinical history were defined as asymp-
tomatic cerebral infarctions.MRI Protocol
The image protocol included T1-weighted, fluid-
attenuated inversion recovery, T2-weighted, and gradient
echo T2*-weighted MRI. Imaging of the brain was per-
formed on three 1.5 T MRI scanners at our hospital, the
Signa Excite (General Electric Medical Systems, Wauke-
sha, WI), Magnetom Sonata (Siemens Medical Solutions,
Munich, Germany), and Achieva MR (Philips Healthcare,
Bothell, WA) scanners. The gradient echo sequence
parameters for the Signa Excite were as follows: 22 axial
images; field of view, 220 mm; slice thickness, 5.5 mm;
Table 1. Profiles of patients assorted according to the medications used against cardiogenic embolism
Characteristic
NOAC Warfarin Warfarin + AP AP None
N 5 23 N 5 21 N 5 9 N 5 9 N 5 7
Congestive heart failure 10 (43.5%) 8 (38.1%) 6 (66.7%) 5 (55.6%) 1 (14.3%)
Hypertension 15 (65.2%) 11 (52.4%) 7 (77.8%) 5 (55.6%) 3 (42.9%)
Age $ 75 y 11 (47.8%) 11 (52.4%) 5 (55.6%) 4 (44.4%) 2 (28.6%)
Diabetes mellitus 3 (13.0%) 7 (33.3%) 2 (22.2%) 3 (33.3%) 1 (14.3%)
Stroke/TIA 3 (13.0%) 3 (14.3%) 1 (11.1%) 0 2 (28.6%)
Vascular disease 3 (13.0%) 4 (19.0%) 3 (33.3%) 3 (33.3%) 1 (14.3%)
Age 65 to 74 y 16 (70.0%) 17 (81.0%) 9 (100.0%) 6 (66.7%) 5 (71.4%)
Sc (female sex) 6 (26.1%) 8 (38.1%) 2 (22.2%) 3 (33.3%) 1 (14.3%)
Chronic kidney disease 7 (30.4%) 12 (57.1%) 7 (77.8%) 3 (33.3%) 1 (14.3%)
Baseline CMBs 8 (34.8%) 12 (57.1%) 3 (33.3%) 2 (22.2%) 2 (28.6%)
Baseline ACIs 5 (21.7%) 8 (38.1%) 4 (44.4%) 1 (11.1%) 3 (42.9%)
Development of CMBs 0 5 (23.8%) 3 (33.3%) 0 1 (14.3%)
Development of ACIs 2 (8.7%) 2 (9.5%) 1 (11.1%) 0 0
Abbreviations: NOAC, non-vitamin K antagonist oral anticoagulants; AP, antiplatelets; Sc, sex category; TIA, transient ischemic attack;
CMBs, cerebral microbleeds; ACIs, asymptomatic cerebral infarcts.
NOACS DO NOT INCREASE CMBS 1375interslice gap, 1.0 mm; 2563 256matrix; echo time, 20 ms;
repetition time, 640 ms; and flip angle, 20. For the
Magnetom Sonata, the parameters were 22 axial
images; repetition time, 600 ms; echo time, 18 ms; slice
thickness, 5.5 mm; interslice gap, 1.0 mm; field of view,
175 3 200 mm; and flip angle, 20; and for the Achieva
MR scanner, the parameters were repetition time,
700 ms; echo time, 20 ms; slice thickness, 5.5 mm; inter-
slice gap, 1.0 mm; field of view, 210 mm; and flip
angle, 20.Statistical Analysis
Statistical analyses were performed using SPSS, version
11.0 software (SPSS Inc., Chicago, IL). The Fisher exact
test, chi-square test for dichotomous variables, or the
Kruskal-Wallis test for ranked data were used for the
group comparisons. The hazard ratio and 95% confidence
interval (CI) of the development of the CMBs was
obtained using a logistic regression analysis with the
forced entry method. In this regard, the clinical variables
with a P less than .10 in the univariate analysis were
entered into the multivariate analysis. Finally, we consid-
ered a P less than .05 statistically significant.Results
Sixty-nine patients were enrolled and repeated MRI
examinations at 1-year interval (Table 1). There were 23
AF patients with NOACs including 1 with apixaban
10 mg, 1 with apixaban 5 mg, 1 with dabigatran 300 mg,
11 with dabigatran 220 mg, 5 with rivaroxaban 15 mg,
and 4 with rivaroxaban 10 mg. CMBs newly developed
in 13.0% of the whole patients (9 of 69). Among the 9CMBs, 6 were lobar CMBs and 3 were deep or infratento-
rial CMBs.
No CMBs developed in the 23 patients with NOACs for
a year. Nine patients with antiplatelets also did not
develop any CMBs. On the other hand, among the 21
patients with warfarin, 3 had newly developed CMBs.
Moreover, 3 of 9 patients with warfarin and antiplatelets
incurred CMBs. The incidence of CMBs significantly
differed among the groups (P 5 .04). The proportion of
patients with chronic kidney disease and paroxysmal
AF differed significantly among the groups, respectively.
On the other hand, the duration of AF and the number of
baseline CMBs did not differ significantly among each
group. The duration of taking warfarin before this study
among the groups of NOACs, warfarin, and warfarin
with antiplatelets also did not differ significantly.
When divided into 2 groups according to whether the
CMBs developed, significant differences in the incidence
of the use of NOACs and warfarin were observed
between the 2 groups (Table 2). Because there were no
AF patients with NOACs who developed CMBs, the haz-
ard ratios of NOACs were impossible to calculate based
on either a univariate or multivariate analysis. A multi-
variate regression analysis showed that only warfarin
was independently related to the new development of
CMBs (hazard ratio, 10.75; 95% CI, 1.22-94.99; P 5 .03;
Table 2). No symptomatic CIs were observed in either
group during the follow-up duration.Discussion
The present findings demonstrated the possibility that
NOACs do not increase CMBs in AF patients in a pro-
spective manner.
Table 2. Statistical analysis of 69 patients and the variates appertaining to the development of CMBs
Variates n 5 9
Fisher’s exact test
Logistic regression analysis
Univariate Multivariate
P OR (95% CI) P HR (95% CI) P HR (95% CI)
Congestive heart failure 4 1.00 1.05 (.28-4.00) .95 1.05 (.26-4.29)
Hypertension 5 1.00 .83 (.22-3.18) .80 .83 (.20-3.42)
Age $75 y 6 .29 2.44 (.60-9.76) .24 2.44 (.56-10.70)
Diabetes mellitus 4 .20 3.20 (.80-12.95) .12 3.20 (.74-13.77)
Stroke/TIA 1 1.00 1.13 (.16-8.41) .85 .81 (.09-7.39)
Vascular disease 2 1.00 .67 (.15-3.17) .88 1.14 (.21-6.22)
Age 65-74 y 8 .67 2.67 (.39-17.45) .37 2.67 (.31-23.11)
Sc (female sex) 2 1.00 .67 (.15-3.17) .63 .87 (.13-3.53)
Chronic kidney disease 4 1.00 1.05 (.28-4.00) .95 1.05 (.26-4.29)
NOAC 0 .02 NA 1.00 NA
Warfarin 8 .01 13.82 (2.05-89.48) .02 13.82 (1.62-117.93) .03 10.75 (1.22-94.99)
Antiplatelets 3 .69 1.50 (.37-6.28) .60 1.50 (.33-6.75)
Baseline CMBs 5 .14 3.71 (.91-14.96) .08 3.71 (.84-16.38) .30 2.38 (.47-12.00)
Baseline ACIs 6 .12 3.44 (.88-13.45) .09 3.44 (.82-14.42) .34 2.12 (.45-10.62)
Abbreviations: ACIs, asymptomatic cerebral infarcts; CI, confidence interval; CMBs, cerebral microbleeds; HR, hazard ratio; NA, not appli-
cable; NOAC, non-vitamin K antagonist oral anticoagulants; OR, odds ratio; TIA, transient ischemic attack.
The table is divided into 3 broad parts according to the type of analytical method.
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One of the most important findings of this study was
the fact that no AF patients with NOACs developed
CMBs in the space of a year. CMBs have been considered
to represent perivascular accumulation of hemosiderin-
containing macrophages as a corollary of extravasated
erythrocytes from cerebral small vessels.15 We prospec-
tively clarified that patients with AF showed a signifi-
cantly higher prevalence of CMBs, but the presence of
CMBs in the baseline MRI was highly predictive of the
consequent onset of an asymptomatic cerebral infarction
and an increase in CMBs in patients with AF.13 CMBs
have been described in association with a number of con-
ditions reflecting the vulnerability of cerebral small ves-
sels and that overlap with the CHA2DS2-VASc score: an
older age, hypertension, smoking, lacunar infarcts, prior
ischemic strokes or intracranial hemorrhages, white
matter disease, and Alzheimer disease.16 However, each
element of the CHA2DS2-VASc score was not associated
with the new onset of CMBs in the present study. Despite
some pathophysiological mechanism of AF itself
enhancing the vulnerability of cerebral small vessels,
the AF patients with NOACs did not develop CMBs for
1 year in the present study. We continue further con-
sideration in the future study with a much longer
follow-up and accumulation of cases.
CMBs were categorized by their location based on pre-
sumed differences in the underlying etiology: deep or in-
fratentorial CMBswere thought to represent hypertensive
arteriopathy, whereas lobar CMBs pointed toward cere-
bral amyloid angiopathy.17 In the present study, CMBswere found more often in lobar areas than deep or infra-
tentorial areas. Lobar CMBs are detected in a significant
proportion of the AF patients according to a recent
report.18 We considered the influence of CMBs in the
2 categories together because of the moderate cases
this time.
Relationship between NOACs and CMBs
In the present study, NOACs were significantly nega-
tively associated with the development of CMBs by a
Fisher’s exact test; however, they were not considered sig-
nificant according to a multivariate regression analysis
because of the statistical nature. On the one hand, as
mentioned earlier, warfarin was significantly related to
the development of CMBs in the present study. If warfarin
increases CMBs, the difference in the preliminary
warfarin exposure might affect the development of
CMBs during this study period. However, we clarified
that the advance duration of taking warfarin did not
differ among the groups.
Warfarin exerts an anticoagulation effect by the inhibi-
tion of the vitamin K–dependent synthesis of coagulation
factors II, VII, IX, and X and regulatory factor proteins
C and S. NOACs, including the direct thrombin
inhibitor (dabigatran) and factor Xa inhibitors (rivaroxa-
ban, apixaban, and edoxaban), do not influence factor
VII. A complex formation of the tissue factor and acti-
vated coagulation factor VII is an important initiator
of the coagulation cascade. The tissue factor is at a high
concentration in the brain and, thereby, is thought to
be a protective factor against cerebral hemorrhages.19 In
NOACS DO NOT INCREASE CMBS 1377fact, it has been reported that NOACs do not increase
symptomatic cerebral hemorrhages.1-3 It is also well
known that the presence of CMBs predicts future
cerebral hemorrhages. In line with this, it may be highly
possible that NOACs do not harm the cerebral small
vessels and, therefore, can cause less CMBs. Further-
more, the performance of NOACs is independent of
prior warfarin exposure.
Whether antiplatelets increase CMBs is a disputed
question. The CMBs seemed to have statistically been un-
affected by the antiplatelets alone in this study; however;
a remarkable 3 of 9 patients with both warfarin and anti-
platelets had CMBs. The result agrees with the well-
known clinical fact that the combination use of warfarin
and antiplatelets significantly augments intracerebral
hemorrhages.20 Although the duration of AF and number
of baseline CMBs also hold the potential to affect
the development of CMBs pathologically as mentioned
earlier, a comparison among the groups did not show
any significant differences. It is true that the proportion
of patients with paroxysmal AF significantly differed
among the 5 groups; however, there did not seem to be
a difference among the groups of NOACs, warfarin, and
warfarin with antiplatelets.
This study had several limitations. First, the results of
this preliminary challenging report have limited effective-
ness because of the small number of cases and short
period of follow-up. However, the practical use of
NOACs has not been for long yet. To determine the asso-
ciation between CMBs and AF with a sufficient statistical
power, more patients must be studied for a longer dura-
tion as a large clinical trial. Second, we employed 3 types
of MRI systems in the present study. Ideally, all the imag-
ing should have been processed by a single MRI system.
Accordingly, we very cautiously performed a compara-
tive review of the MR images.
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